Millipore Sigma Vibrant Logo
Attenzione: Ci siamo trasferiti. Non è più possibile acquistare i prodotti Merck Millipore nel sito MerckMillipore.comPer saperne di più

203900 Bufalin - CAS 465-21-4 - Calbiochem

A cardiotonic steroid isolated from toads of Bufo species that potently inhibits ouabain-sensitive Na+,K+-ATPase activity (IC₅₀ = 1.4 nM).

Bufalin - CAS 465-21-4 - Calbiochem: MSDS (material safety data sheet) o SDS, certificato d’analisi (CoA) e certificato di qualità (CoQ), dossier, brochure e altri documenti disponibili.

Sinonimi: 5β, 20(22)-Bufadienolide-3β, 14-diol

Primary Target: Ouabain-sensitive Na+,K+-ATPase activity
203900
Purchase on Sigma-Aldrich

Panoramica

Replacement Information

Tabella delle specifiche principali

CAS #Empirical Formula
465-21-4C₂₄H₃₄O₄

Products

Numero di catalogoConfezionamento Qtà/conf
203900-10MG Fusto in alluminio 10 mg
Description
OverviewA cardiotonic steroid isolated from toads of Bufo species that potently inhibits ouabain-sensitive Na+,K+-ATPase activity (IC50 = 1.4 nM). Induces apoptosis in various human cell lines such as leukemia HL-60 and U937 cells by altering the expression of apoptosis-related genes. Reported to stimulate the activities of p21 activated kinase (PAK) and c-Jun Kinase (JNK) in leukemic cell lines. Induces a transient increase in the expression of Tiam1 mRNA in U937 cell lines (~100 nM). Bufalin also down-regulates gene expression of the intracellular signaling protein 14-3-3 in rat lens, probably a consequence of Na+,K+-ATPase inhibition. Reduces the level of topoisomerase II in human leukemia cells.
Catalogue Number203900
Brand Family Calbiochem®
Synonyms5β, 20(22)-Bufadienolide-3β, 14-diol
References
ReferencesKurosawa, M., et al. 2000. Am. J. Physiol. 278, C500.
Kawazoe, N., et al. 1999. Oncogene 18, 2413.
McGowan, M.H., et al. 1999. J. Pharmacol. Exp. Ther. 289, 1559.
Watabe, M., et al. 1998. Oncogene 16, 779.
Hashimoto, S., et al. 1997. Leuk. Res. 21, 875.
Morris, J.F., et al. 1997. Comp. Biochem. Physiol. A Physiol. 118, 599.
Brownlee, A.A., et al. 1990. Clin. Sci. 78, 169.
Product Information
CAS number465-21-4
ATP CompetitiveN
FormWhite to off-white solid
Hill FormulaC₂₄H₃₄O₄
Chemical formulaC₂₄H₃₄O₄
ReversibleN
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetOuabain-sensitive Na+,K+-ATPase activity
Primary Target IC<sub>50</sub>1.4 nM against ouabain-sensitive Na+,K+-ATPase activity
Purity≥98% by HPLC
Physicochemical Information
Cell permeableN
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
RTECSEI2962500
Safety Information
R PhraseR: 26/27/28

Very toxic by inhalation, in contact with skin and if swallowed.
S PhraseS: 22-36/37/39-45

Do not breathe dust.
Wear suitable protective clothing, gloves and eye/face protection.
In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Highly Toxic
Hazardous Materials Attention: Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
Storage -20°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Numero di catalogo GTIN
203900-10MG 04055977219937

Documentation

Bufalin - CAS 465-21-4 - Calbiochem MSDS

Titolo

Scheda di sicurezza (MSDS) 

Bufalin - CAS 465-21-4 - Calbiochem Certificati d'Analisi

TitoloNumero di lotto
203900

Riferimenti bibliografici

Panoramica delle referenze
Kurosawa, M., et al. 2000. Am. J. Physiol. 278, C500.
Kawazoe, N., et al. 1999. Oncogene 18, 2413.
McGowan, M.H., et al. 1999. J. Pharmacol. Exp. Ther. 289, 1559.
Watabe, M., et al. 1998. Oncogene 16, 779.
Hashimoto, S., et al. 1997. Leuk. Res. 21, 875.
Morris, J.F., et al. 1997. Comp. Biochem. Physiol. A Physiol. 118, 599.
Brownlee, A.A., et al. 1990. Clin. Sci. 78, 169.
Scheda tecnica

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision22-May-2008 RFH
Synonyms5β, 20(22)-Bufadienolide-3β, 14-diol
DescriptionA cardiotonic steroid isolated from Bufo species toads that potently inhibits ouabain-sensitive Na+,K+-ATPase activity. Induces apoptosis in various human cell lines such as leukemia HL60 and U937 cells by altering the expression of apoptosis-related genes. Reported to stimulate the activities of p21 activated kinase (PAK) and c-Jun Kinase (JNK) in leukemic cell lines. Induces a transient increase in the expression of Tiam1 mRNA in U937 cell lines (~100 nM). Bufalin also down-regulates gene expression of the intracellular signaling protein 14-3-3 in rat lens, probably a consequence of Na+-K+-ATPase inhibitors. Reduces the level of topoisomerase II in human leukemia cells.
FormWhite to off-white solid
Intert gas (Yes/No) Packaged under inert gas
CAS number465-21-4
RTECSEI2962500
Chemical formulaC₂₄H₃₄O₄
Structure formulaStructure formula
Purity≥98% by HPLC
SolubilityDMSO (25 mg/ml) or warm Ethanol (25 mg/ml)
Storage Protect from light
-20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Highly Toxic
ReferencesKurosawa, M., et al. 2000. Am. J. Physiol. 278, C500.
Kawazoe, N., et al. 1999. Oncogene 18, 2413.
McGowan, M.H., et al. 1999. J. Pharmacol. Exp. Ther. 289, 1559.
Watabe, M., et al. 1998. Oncogene 16, 779.
Hashimoto, S., et al. 1997. Leuk. Res. 21, 875.
Morris, J.F., et al. 1997. Comp. Biochem. Physiol. A Physiol. 118, 599.
Brownlee, A.A., et al. 1990. Clin. Sci. 78, 169.